MedTrace Logo

Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

NCT02944019 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13980

Last updated 2022-06-01

No results posted yet for this study

Summary

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the Non-valvular Atrial Fibrillation (NVAF) indication, Daiichi-Sankyo proposed this post-authorization safety study (PASS) to gain insight into the safety (bleeding, liver adverse events, all-cause mortality and other drug related adverse events) of edoxaban use in patients with NVAF who were not preselected.

Conditions

Interventions

DRUG

Edoxaban

Prescribed according to approved label

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2022-04-13
Completion
2022-04-13

Countries

  • Austria
  • Belgium
  • Germany
  • Ireland
  • Italy
  • Netherlands
  • Portugal
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02944019 on ClinicalTrials.gov